Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Tefferi

Showing results (1-10 of 346) with videos related to

Pageof 35
Sort By:
International Journal of Hematology|May 25, 2001
The pathogenesis of chronic myeloproliferative diseasesA Tefferi
Leukemia & Lymphoma|January 1, 1996
Chronic natural killer cell lymphocytosisA Tefferi
Blood|August 8, 1998
Is hydroxyurea leukemogenic in essential thrombocythemia?A Tefferi
Leukemia|April 23, 2013
Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified?A Tefferi
Leukemia Research|April 13, 2001
Recent progress in the pathogenesis and management of essential thrombocythemiaA Tefferi
Leukemia|September 21, 2007
The history of myeloproliferative disorders: before and after DameshekA Tefferi
Acta Haematologica|July 5, 2005
Modern diagnosis and treatment of primary eosinophiliaA Tefferi
Leukemia|April 30, 2010
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1A Tefferi
Seminars in Hematology|February 4, 1999
Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemiaA Tefferi
Mayo Clinic Proceedings|March 9, 1999
Diagnosing polycythemia vera: a paradigm shiftA Tefferi
Pageof 35

Showing results (1-10 of 346) with videos related to

Sort By:
Pageof 35
International Journal of Hematology|May 25, 2001
The pathogenesis of chronic myeloproliferative diseasesA Tefferi
Leukemia & Lymphoma|January 1, 1996
Chronic natural killer cell lymphocytosisA Tefferi
Blood|August 8, 1998
Is hydroxyurea leukemogenic in essential thrombocythemia?A Tefferi
Leukemia|April 23, 2013
Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified?A Tefferi
Leukemia Research|April 13, 2001
Recent progress in the pathogenesis and management of essential thrombocythemiaA Tefferi
Leukemia|September 21, 2007
The history of myeloproliferative disorders: before and after DameshekA Tefferi
Acta Haematologica|July 5, 2005
Modern diagnosis and treatment of primary eosinophiliaA Tefferi
Leukemia|April 30, 2010
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1A Tefferi
Seminars in Hematology|February 4, 1999
Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemiaA Tefferi
Mayo Clinic Proceedings|March 9, 1999
Diagnosing polycythemia vera: a paradigm shiftA Tefferi
Pageof 35